Home
Scholarly Works
Tamoxifen versus tamoxifen plus octreotide LAR as...
Conference

Tamoxifen versus tamoxifen plus octreotide LAR as adjuvant therapy for early-stage breast cancer in postmenopausal women: Update of NCIC CTG MA14 trial.

Authors

Pollak MN; Chapman JW; Pritchard KI; Krook JE; Dhaliwal HS; Vandenberg TA; Whelan TJ; O'Reilly SE; Wilson CF; Shepherd LE

Volume

28

Pagination

pp. 542-542

Publisher

American Society of Clinical Oncology (ASCO)

Publication Date

May 20, 2010

DOI

10.1200/jco.2010.28.15_suppl.542

Conference proceedings

Journal of Clinical Oncology

Issue

15_suppl

ISSN

0732-183X
View published work (Non-McMaster Users)

Contact the Experts team